

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: TOVEY=1A

JLL  
5/30/02

In re Application of:	) Conf. No. 1869
Michael TOVEY	) Art Unit: 1614
Appln. No.: 09/243,030	) Examiner: J. Goldberg
Filed: February 3, 1999	) Washington, D.C.
For: THERAPEUTIC APPLICATIONS OF HIGH DOSE INTERFERON	) February 26, 2002
	) VIA TELEFACSIMILE

## SUPPLEMENTAL AMENDMENT

Honorable Commissioner of Patents  
Washington, D.C. 20231

Sir:

Supplementing applicant's main response to the official action of August 30, 2001, which was filed January 25, 2002, please further amend as follows:

IN THE CLAIMS

Please rewrite claims 38-41, 44 and 44-49 in amended form as follows:

38 (Amended). The method of claim 36 in which the effective dose of interferon is administered in a single dose which is not a multiple or continuous dose.

39 (Amended). The method of claim 36, in which the effective dose of interferon is administered intranasally, in

#20/J  
JLP  
5/30/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

09 | 243,030

In Re Application of: TOVEY, Michael

Art Unit: 1614

Application No.: 09/243,030

Examiner: J. Goldberg

Filed: February 3, 1999

Washington, D.C.

For: THERAPEUTIC APPLICATIONS OF HIGH DOSE INTERFERON

Atty's Docket: TOVEY-1A

Date: February 26, 2002

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231**VIA TELEFACSIMILE**

Sir:

Transmitted herewith is a [ ] Amendment [X] Supplemental Amendment

in the above-identified application.

- [ ] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.  
 No additional fee is required.  
[ ] The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT	(Col. 2)	(Col. 3) HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	+ 30	MINUS	20	10
INDEP.	+ 2	MINUS	3	0
<b>FIRST PRESENTATION OF MULTIPLE DEP. CLAIM</b>				

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$ 180.00
x 84	\$
+ 280	\$
TOTAL	

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

## Small Entity

## Response Filed Within

- [ ] First - \$ 55.00  
[ ] Second - \$ 200.00  
[ ] Third - \$ 460.00  
[ ] Fourth - \$ 720.00

## Month After Time Period Set

## Other Than Small Entity

## Response Filed Within

- [ ] First - \$ 110.00  
[ ] Second - \$ 400.00  
[ ] Third - \$ 920.00  
[ ] Fourth - \$ 1440.00

## Month After Time Period Set

[ ] Less fees (\$\_\_\_\_\_) already paid for \_\_\_\_ month(s) extension of time on \_\_\_\_\_.

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$\_\_\_\_\_.

[ ] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$\_\_\_\_\_.

[ ] A check in the amount of \$\_\_\_\_\_ is attached (check no. ).


The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By:

Roger L. Browdy  
Registration No. 28,018



Faxsimile: (202) 737-3528  
Telephone: (202) 628-5197